Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Premier Biomedical's EBITDA for the
three
months ended in Dec. 2019 was $0.26 Mil. Premier Biomedical's Revenue for the
three
months ended in Dec. 2019 was $0.00 Mil. Therefore, Premier Biomedical's EBITDA margin for the quarter that ended in Dec. 2019 was 25,700.00%.
Premier Biomedical (OTCPK:BIEI) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Premier Biomedical EBITDA Margin % Related Terms
Premier Biomedical EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Premier Biomedical's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BIEI vs PTXTQ, STNN, SBFM: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Premier Biomedical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Premier Biomedical EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Premier Biomedical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Premier Biomedical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Premier Biomedical (BIEI) has a EBITDA Margin % of 25,700.00% as of Dec. 2019. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Premier Biomedical and its competitors.
Is Premier Biomedical's EBITDA Margin % too high?
Premier Biomedical's current EBITDA Margin % is 25,700.00%. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Premier Biomedical's value of 25,700.00% is 205994.6% above this industry median.
How does Premier Biomedical's EBITDA Margin % compare to PTXTQ and STNN?
Premier Biomedical's EBITDA Margin % of 25,700.00% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.47. Premier Biomedical's value of 25,700.00% is 205994.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Premier Biomedical's current EBITDA Margin % of 25,700.00% is 205994.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Premier Biomedical and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Premier Biomedical's current EBITDA Margin % is 25,700.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Premier Biomedical stock overvalued right now?
Premier Biomedical (BIEI) has a current EBITDA Margin % of 25,700.00%. The current EBITDA Margin % is 25,700.00% and 205994.6% above the Drug Manufacturers industry median of 12.47. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Premier Biomedical (BIEI), the current EBITDA Margin % is 25,700.00% as of Dec. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Premier Biomedical Inc is engaged in a hemp based initiative, developing graphene enhanced formulations for a myriad of commercial and military applications and complementing new EV battery technology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIEI has been successfully added to your 
